ABEO

Abeona Therapeutics (ABEO)

About Abeona Therapeutics (ABEO)

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Details

Daily high
$6.55
Daily low
$6.15
Price at open
$6.28
52 Week High
$9.01
52 Week Low
$3.05
Market cap
271.6M
Dividend yield
0.00%
Volume
142,808
Avg. volume
292,583
P/E ratio
-2.46

Abeona Therapeutics News

Details

Daily high
$6.55
Daily low
$6.15
Price at open
$6.28
52 Week High
$9.01
52 Week Low
$3.05
Market cap
271.6M
Dividend yield
0.00%
Volume
142,808
Avg. volume
292,583
P/E ratio
-2.46